Changing pattern of care of boys with haemophilia in western European centres
- PMID: 15810909
- DOI: 10.1111/j.1365-2516.2005.01074.x
Changing pattern of care of boys with haemophilia in western European centres
Abstract
Haemophilia management is not uniform among countries, even within western Europe, that have close economic, social and cultural relationship. The European Paediatric Network PedNet aims to share experiences in the field of the care of boys with haemophilia. In 1998, a PedNet survey has shown significant disparities in 20 centres from 16 countries, particularly as regards the implementation of prophylaxis regimen. This survey has been updated in 2003 to describe the current status of haemophilia management in 22 centres and the changing pattern of care of boys with severe haemophilia in western Europe. Regular, continuous long-term prophylaxis is provided in all PedNet centres, more than 50% and 80-100% of boys being treated this way in 20/22 and 15/22 centres respectively. Twenty of the 22 centres (91%) recommend continuous prophylaxis (primary or secondary A) for a new patient. The use of recombinant factor VIII concentrates was already widespread in 1998 and a further expansion of recombinant products has been observed over the last 5 years. Recombinant FVIII is now used exclusively in nine centres and for more than 80% of boys with haemophilia A in nine other centres. The use of recombinant and plasma derived FIX is more balanced: among 18 centres where boys with haemophilia B are treated, 14 use recombinant FIX, and nine administer it to a majority of patients. Other modifications of practice have been stressed in this survey, such as more targeted use of central venous devices in the youngest boys and more extensive characterisation of genetic mutations.
Similar articles
-
Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries.Haemophilia. 2000 Nov;6(6):619-24. doi: 10.1046/j.1365-2516.2000.00427.x. Haemophilia. 2000. PMID: 11122385
-
Optimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia. 2004 Oct;10 Suppl 4:97-104. doi: 10.1111/j.1365-2516.2004.00998.x. Haemophilia. 2004. PMID: 15479380 Review.
-
The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.Haemophilia. 2008 Sep;14(5):923-30. doi: 10.1111/j.1365-2516.2008.01810.x. Epub 2008 Jul 14. Haemophilia. 2008. PMID: 18637844
-
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.Haemophilia. 2004 Nov;10(6):689-97. doi: 10.1111/j.1365-2516.2004.01036.x. Haemophilia. 2004. PMID: 15569163
-
Haemophilia care in Zimbabwe.Cent Afr J Med. 1996 May;42(5):153-6. Cent Afr J Med. 1996. PMID: 8771937 Review.
Cited by
-
New treatments in hemophilia: insights for the clinician.Ther Adv Hematol. 2012 Jun;3(3):165-75. doi: 10.1177/2040620712440007. Ther Adv Hematol. 2012. PMID: 23556123 Free PMC article.
-
Haemophilia.Nat Rev Dis Primers. 2021 Jun 24;7(1):45. doi: 10.1038/s41572-021-00278-x. Nat Rev Dis Primers. 2021. PMID: 34168126 Review.
-
Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women.Int J Womens Health. 2015 Jul 16;7:707-16. doi: 10.2147/IJWH.S83418. eCollection 2015. Int J Womens Health. 2015. PMID: 26213478 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical